Perhaps, also in fit elderly patients with NPM1-mutated AML, venetoclax-based regimens could have the potential to challenge, as frontline treatment, standard intensive chemotherapy, which results in only 15% to 20% long-term survival [7,8,78]. The gene discussed is NPM1; the disease is acute myeloid leukemia.